Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?

Benzer Materyaller

• Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy
  Yazar:: Noronha, Vanita, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
  Yazar:: Joshi, Amit, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
  Yazar:: Patil, Vijay Maruti, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of a Phase III randomized trial to compare the benefit of gefitinib versus pemetrexed/carboplatin for epidermal growth factor receptor-mutated non-small cell lung cancer
  Yazar:: Vijay Patil, ve diğerleri
  Baskı/Yayın Bilgisi: (2019-01-01)
• Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
  Yazar:: Noronha, Vanita, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)